Spectral AI Added to Russell Microcap® Index
Spectral AI, Inc. (Nasdaq: MDAI) has been included in the Russell Microcap Index as of July 1, 2024, following the annual index reconstitution. This inclusion marks a significant milestone for the Dallas-based AI company, which specializes in medical diagnostics.
Key Points:
- Index Inclusion: Spectral AI’s entry into the Russell Microcap Index is expected to increase its visibility among investors.
- Product Development: The company is advancing its DeepView System, an AI-driven medical device for assessing wound healing, targeting applications for burns and diabetic foot ulcers.
- Clinical Progress: Spectral AI is nearing completion of a pivotal clinical study for the burn application of its system, with FDA approval anticipated in 2025.
“Spectral AI’s addition to the Russell Microcap® Index provides us with greater visibility among investors at this important time in our history,” said Peter M. Carlson, Chief Executive Officer of Spectral AI. “We continue to build momentum in commercializing our proprietary, AI-driven DeepView System and remain focused on creating long-term value for our shareholders.”
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. DeepView is a predictive medical device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
